Nilotinib Stada (Nilotinib)

Nilotinib binds selectively to the ATP‑binding pocket of the BCR‑ABL fusion protein, blocking its tyrosine kinase activity. This inhibition stops downstream signaling pathways that promote leukemic cell growth and survival, leading to apoptosis and disease control in CML.

The prescribed dose of Nilotinib is determined by the treating physician based on the patient’s disease phase, prior therapy and individual tolerance. Dosage adjustments may be made according to clinical response and safety monitoring.

Nilotinib is classified as contraindicated during pregnancy and breastfeeding because it may cause fetal harm and is excreted in breast milk. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided while on therapy.

To order Nilotinib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation tyrosine kinase inhibitor that offers higher potency against BCR‑ABL than first‑generation agents such as imatinib. It provides faster and deeper molecular responses, particularly in patients who are resistant or intolerant to imatinib, but it also carries a distinct safety profile that requires cardiac monitoring.

Nilotinib Stada tablets should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the product in its original container until use, and avoid exposure to excessive heat or humidity to maintain stability.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal. The tablets should be swallowed with water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, arterial occlusive events such as peripheral arterial disease, severe hepatotoxicity, pancreatitis, and profound neutropenia. Prompt reporting of cardiac symptoms, liver or pancreatic discomfort, and signs of infection is essential.

Nilotinib should not be used by patients with a known hypersensitivity to the drug or any of its excipients, those with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment. It is also contraindicated in pregnant or nursing women.